ReNeuron Group plc New Scientific Advisory Board (0070V)
April 03 2023 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 0070V
ReNeuron Group plc
03 April 2023
ReNeuron Group plc
("ReNeuron" or the "Company")
New Scientific Advisory Board
ReNeuron Group plc (AIM: RENE) , a UK-based leader in stem cell
derived exosome technologies , announces the appointment of Prof.
Giuseppe (Beppe) Battaglia, Prof. Edit I Buzás, Prof. Dr. rer. Nat.
Bernd Giebel and Prof. Kenneth W. Witwer to a newly established
Scientific Advisory Board (SAB), chaired by Prof. Stefano
Pluchino.
This new SAB, composed of leading academics and industry
executives, brings a world-class breadth of expertise across the
extracellular vesicle (EV) field. Its role is to advise the Company
on scientific matters relating to its exosome platform research and
development strategy.
For additional information on ReNeuron's Scientific Advisory
Board and its members, please visit the Company's website via the
following link: https://www.reneuron.com/about-us/advisory-board/
.
Stefano Pluchino, Chair of the SAB, commented: "I am delighted
that we have attracted such renowned EV experts to join the
ReNeuron SAB and it is a privilege to be the Chair of the board. I
very much look forward to working alongside them and the Company as
we seek to progress the development of the Company's stem
cell-derived exosome-based drug delivery platform.
"On behalf of the Company, I would also like to take the
opportunity to thank the former members of the old Scientific
Advisory Board for all the advice and support provided during their
membership."
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors
Iain Ross, Executive Chairman Via Walbrook PR
John Hawkins, Chief Financial Officer
Allenby Capital Limited (Nominated
Adviser and Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Stefano Aquilino (Sales & Corporate
Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804
654
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived,
exosome-based, drug delivery platform with customisable cellular
targeting capabilities for the delivery of complex drug
modalities.
Through the generation of several unique and scalable exosome
producer cell lines, our CustomEX(TM) platform can be optimised for
specific tissues targets and payloads leading to improvements in
therapeutic outcome and a reduction in off-target effects. ReNeuron
offers a delivery mechanism for a variety of payloads such as
siRNA, mRNA, proteins, small molecules and genes. Through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform, the Company can make allogeneic tissue cells of choice
and has the potential to produce exosomes with tissue specific
targeting ability.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZGFFDMZGFZM
(END) Dow Jones Newswires
April 03, 2023 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Reneuron (LSE:RENE)
Historical Stock Chart
From Jan 2024 to Jan 2025
